These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23892662)

  • 1. A new player SETs in myeloid malignancy.
    Trimarchi T; Ntziachristos P; Aifantis I
    Nat Genet; 2013 Aug; 45(8):846-7. PubMed ID: 23892662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of subclonal SETBP1 and JAK3 mutations in juvenile myelomonocytic leukemia using droplet digital PCR.
    Wakamatsu M; Okuno Y; Murakami N; Miwata S; Kitazawa H; Narita K; Kataoka S; Ichikawa D; Hamada M; Taniguchi R; Suzuki K; Kawashima N; Nishikawa E; Narita A; Nishio N; Kojima S; Muramatsu H; Takahashi Y
    Leukemia; 2021 Jan; 35(1):259-263. PubMed ID: 32307441
    [No Abstract]   [Full Text] [Related]  

  • 3. Somatic SETBP1 mutations in myeloid malignancies.
    Makishima H; Yoshida K; Nguyen N; Przychodzen B; Sanada M; Okuno Y; Ng KP; Gudmundsson KO; Vishwakarma BA; Jerez A; Gomez-Segui I; Takahashi M; Shiraishi Y; Nagata Y; Guinta K; Mori H; Sekeres MA; Chiba K; Tanaka H; Muramatsu H; Sakaguchi H; Paquette RL; McDevitt MA; Kojima S; Saunthararajah Y; Miyano S; Shih LY; Du Y; Ogawa S; Maciejewski JP
    Nat Genet; 2013 Aug; 45(8):942-6. PubMed ID: 23832012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group.
    Bresolin S; De Filippi P; Vendemini F; D'Alia M; Zecca M; Meyer LH; Danesino C; Locatelli F; Masetti R; Basso G; Te Kronnie G
    Oncotarget; 2016 May; 7(20):28914-9. PubMed ID: 26980750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.
    Sakaguchi H; Okuno Y; Muramatsu H; Yoshida K; Shiraishi Y; Takahashi M; Kon A; Sanada M; Chiba K; Tanaka H; Makishima H; Wang X; Xu Y; Doisaki S; Hama A; Nakanishi K; Takahashi Y; Yoshida N; Maciejewski JP; Miyano S; Ogawa S; Kojima S
    Nat Genet; 2013 Aug; 45(8):937-41. PubMed ID: 23832011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.
    Stieglitz E; Troup CB; Gelston LC; Haliburton J; Chow ED; Yu KB; Akutagawa J; Taylor-Weiner AN; Liu YL; Wang YD; Beckman K; Emanuel PD; Braun BS; Abate A; Gerbing RB; Alonzo TA; Loh ML
    Blood; 2015 Jan; 125(3):516-24. PubMed ID: 25395418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SETBP1 mutations in juvenile myelomonocytic leukaemia and myelodysplastic syndrome but not in paediatric acute myeloid leukaemia.
    Shiba N; Ohki K; Park MJ; Sotomatsu M; Kudo K; Ito E; Sako M; Arakawa H; Hayashi Y
    Br J Haematol; 2014 Jan; 164(1):156-9. PubMed ID: 24117422
    [No Abstract]   [Full Text] [Related]  

  • 8. Somatic SETBP1 mutations in myeloid neoplasms.
    Makishima H
    Int J Hematol; 2017 Jun; 105(6):732-742. PubMed ID: 28447248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome.
    Norton A; Fisher C; Liu H; Wen Q; Mundschau G; Fuster JL; Hasle H; Zeller B; Webb DK; O'Marcaigh A; Sorrell A; Hilden J; Gamis A; Crispino JD; Vyas P
    Blood; 2007 Aug; 110(3):1077-9. PubMed ID: 17644747
    [No Abstract]   [Full Text] [Related]  

  • 10. Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.
    Sachs Z; Been RA; DeCoursin KJ; Nguyen HT; Mohd Hassan NA; Noble-Orcutt KE; Eckfeldt CE; Pomeroy EJ; Diaz-Flores E; Geurts JL; Diers MD; Hasz DE; Morgan KJ; MacMillan ML; Shannon KM; Largaespada DA; Wiesner SM
    Haematologica; 2016 Oct; 101(10):1190-1199. PubMed ID: 27418650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia.
    Carratt SA; Braun TP; Coblentz C; Schonrock Z; Callahan R; Curtiss BM; Maloney L; Foley AC; Maxson JE
    Leukemia; 2021 Dec; 35(12):3594-3599. PubMed ID: 34002029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guest Editorial: Understanding of MPN and MDS/MPN based on molecular pathogenesis and clinical aspects.
    Harada H
    Int J Hematol; 2017 Jun; 105(6):709-710. PubMed ID: 28447249
    [No Abstract]   [Full Text] [Related]  

  • 13. [Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].
    Senín A; Arenillas L; Martínez-Avilés L; Fernández-Rodríguez C; Bellosillo B; Florensa L; Besses C; Álvarez-Larrán A
    Med Clin (Barc); 2015 Jun; 144(11):487-90. PubMed ID: 24854193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
    Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
    Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations and promoter methylation status of NPM1 in myeloproliferative disorders.
    Oki Y; Jelinek J; Beran M; Verstovsek S; Kantarjian HM; Issa JP
    Haematologica; 2006 Aug; 91(8):1147-8. PubMed ID: 16870548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies.
    Winkelmann N; Schäfer V; Rinke J; Kaiser A; Ernst P; Scholl S; Hochhaus A; Ernst T
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2511-2519. PubMed ID: 28913558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression.
    Fernandez-Mercado M; Pellagatti A; Di Genua C; Larrayoz MJ; Winkelmann N; Aranaz P; Burns A; Schuh A; Calasanz MJ; Cross NC; Boultwood J
    Br J Haematol; 2013 Oct; 163(2):235-9. PubMed ID: 23889083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNMT3A mutations are rare in childhood acute myeloid leukaemia, myelodysplastic syndromes and juvenile myelomonocytic leukaemia.
    Shiba N; Taki T; Park MJ; Shimada A; Sotomatsu M; Adachi S; Tawa A; Horibe K; Tsuchida M; Hanada R; Tsukimoto I; Arakawa H; Hayashi Y
    Br J Haematol; 2012 Feb; 156(3):413-4. PubMed ID: 21981547
    [No Abstract]   [Full Text] [Related]  

  • 19. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.
    Damm F; Itzykson R; Kosmider O; Droin N; Renneville A; Chesnais V; Gelsi-Boyer V; de Botton S; Vey N; Preudhomme C; Clavert A; Delabesse E; Park S; Birnbaum D; Fontenay M; Bernard OA; Solary E
    Leukemia; 2013 Jun; 27(6):1401-3. PubMed ID: 23443343
    [No Abstract]   [Full Text] [Related]  

  • 20. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.
    Puda A; Milosevic JD; Berg T; Klampfl T; Harutyunyan AS; Gisslinger B; Rumi E; Pietra D; Malcovati L; Elena C; Doubek M; Steurer M; Tosic N; Pavlovic S; Guglielmelli P; Pieri L; Vannucchi AM; Gisslinger H; Cazzola M; Kralovics R
    Am J Hematol; 2012 Mar; 87(3):245-50. PubMed ID: 22190018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.